Projects

GIR Projects


ONGOING PROJECTS

INTERNATIONAL:

– Title: Mitochondrial mapping: Evolution-Age-Gender-Lifestyle-Environment (MITOEAGLE).

• Funding Agency: EU – Cost Actions.

• Reference: CA15203 Dates: 12/09/2016-11/09/2020

• PI: Erich Gnaiger, Medical University of Innsbruck, Austria.

• GIR Partner PI: Francisco Javier Blanco García.

• Website: http://www.mitoglobal.org/index.php/MITOEAGLE

    http://www.cost.eu/COST_Actions/ca/CA15203

• Abstract: The objective of MITOEAGLE network is to improve our knowledge on mitochondrial function in health and disease related to Evolution, Age, Gender, Lifestyle and Environment. Every study of mitochondrial (mt) function and disease is faced with EAGLE as the essential background conditions characterizing the individual patient, subject, study group, species, tissue or even cell line. To address the complex interrelationships of EAGLE with an initial focus on humans and rodent models, the network will enhance the value of each individual study by starting to analyse and catalog data beyond the published record. Highlighting the topic of gender and mitochondrial function, unique new information will emerge on human biology from the development of a European reference database.

 

– Title: Bioengineering Networking Institute for Health Aging (IBEROS).

• Funding Agency: EU – Interreg Spain-Portugal, POCTEP.

• Reference: 0245_IBEROS_1_E Dates: 01/10/2015-31/09/2019 Budget: €1.46M

• PI: Pío González Fernández, University of Vigo.

• GIR Partner PI: Joana Cristina Silva Magalhaes.

• Website:

http://iberos.imaisd.es/

http://www.poctep.eu/es/2014-2020/instituto-de-bioingenier%C3%ADa-en-red-para-el-envejecimiento-saludable

• Members of team involved: Joana Magalhaes, Elena F. Burguera, Paula Casal Beiroa, Noa Goyanes Rey, Tamara Hermida, Natividad Oreiro.

• Abstract: IBEROS is a networking interdisciplinary center formed by 13 groups from 8 entities from the North of Portugal and Galicia. The main goal is to promote research and innovation in the areas of Bioengineering (Biomaterials, Nanotechnology and Biosensors) to accomplish technological solutions that contribute to improve the quality of life and health of the population, specially focused on aging-associated diseases. GIR main activity in this project is to discover optical biomarkers for the early diagnosis of OA and new marine drugs with chondrogenic activity.

 

– Title: Applied public-private research enabling osteoarthritis clinical headway (APPROACH).

• Funding Agency: EU – IMI/ EFPIA.

• Reference: IMI-115770-2-APPROACH Dates: 01/06/2015 – 31/11/2020 Budget: €17.5M

• PI: Jonathan Larkin (GlaxoSmithKline, United Kingdom, Coordinator) & Harrie Weinans (UMC Utrecht, The Netherlands, managing entity).

• GIR Partner PI: Francisco Javier Blanco García.

• Website: https://www.approachproject.eu/

• Members of team involved: Joana Magalhaes, Cristina Ruiz Romero, Ignacio Rego, Natividad Oreiro, Carlos Tilve.

• Abstract: The APPROACH project brings together European clinical centers, basic research institutes, small- and medium-sized businesses and pharmaceutical companies. Together, they will combine biomedical data from more than 10.000 people with and without osteoarthritis into a unified bioinformatics platform with the aim of identifying different OA phenotypes. These phenotypes will then be validated in a longitudinal cohort using existing and newly-developed biomarkers. This will allow for the development of guidelines for differentially diagnosing the right patient for the right treatment.

– Title: Studies of Joint Aging and Osteoarthritis.

Funding Agency: National Institute of Aging / National Institute of Health.

Reference: – Dates: 01/04/2009- 03/04/2020 Budget: $11.832.399

PI: Martin Lotz.

GIR Partner PI: Beatriz Caramés.

Members of team involved: 1.

Abstract: The overall goal of this program is to begin with phenotype identification, proceed to elucidation of mechanisms and key cellular and molecular abnormalities in order to provide new directions for correction of aging-associated risk factors for OA and therapeutic interventions for established OA. In this project we focus on the identification of early changes in cellular and joint homeostasis mechanisms upon which OA is triggered or accelerated in response to biomechanical or biochemical stressors.

– Title: Circulating mtDNA as a potential biomarker of osteoarthritis progression.

– Title: Characterization of rapid progression phenotype of knee OA: association with mtDNA haplogroups.

 

NATIONAL:

– Title: Development and clinical validation of an early OA diagnosis kit.

Original Title: Desarrollo y validación clínica de un kit para el diagnóstico precoz de la artrosis.

Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

Reference: DTS17/00200 Dates: 01/01/2018- 31/12/2019 Budget: 75.350€

PI: Francisco Javier Blanco García.

Members of team involved: Natividad Oreiro; Cristina Ruiz Romero; Patricia Fernández Puente; Valentina Calamia; Elena Fernández Burguera.

Abstract: The project proposes the development and clinical validation of a kit for the early diagnosis of OA. This kit is based on suspension beads arrays capable of analyzing simultaneously a panel of 20 circulating proteins with potential OA-biomarker value that have been previously identified by our group. The project will initially develop a semi-quantitative multiplex analysis kit, which will be evaluated in a blind analysis on sera from the PROCOAC cohort, and then the best candidates will be selected for a final quantitative kit that will be validated for clinical use in samples from the incidence cohort of the OsteoArthritis Initiative (OAI).

 

– Title: Identification of mitochondrial genetic markers of rapid progression of knee OA by next generation sequencing techniques.

• Original Title: Identificación de marcadores genéticos mitocondriales de progresión rápida de artrosis de rodilla mediante técnicas de secuenciación masiva.

Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

Reference: PI17/00210 Dates: 01/01/2018- 31/12/2020 Budget: 212.657,50 €

PI: Ignacio Rego Pérez.

Members of team involved: Ignacio Rego Pérez, Mercedes Fernández Moreno, Natividad Oreiro Villar, Juan Fernández Tajes, Morena Scotece, Elisabeth Lamas Rivero.

Abstract: There are OA patients that remain relatively stable over time whilst others progress in a rapid and severe way, achieving a rapid increase of their KL grade in less than 48 months (rapid progressors). Mitochondrial haplogroups condition the rate of incidence and progression of OA, however, the influence of the mitochondrial genetics, as well as the consequences of its interactions with nuclear polymorphisms, in the rate of rapid progression is unknown. Therefore, the aim of this study is to identify mitochondrial genetic variants related to rapid progression in a prospective cohort of OA patients by means of next generation sequencing techniques and to explore potential interactions between mitochondrial polymorphisms and the most robust nuclear polymorphisms related to OA susceptibility.

 

– Title: Identification and validation of circulating predictive biomarkers of response to biological therapy strategies in patients with rheumatoid arthritis (BIO-RESTER).

Original title: Identificación y validación de biomarcadores circulantes predictivos de respuesta a estrategias de terapia biológica e pacientes con artritis reumatoide. (BIO-RESTER).

Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

Reference: PI17/00404 Dates: 01/01/2018- 31/12/2020 Budget: 123.420 €

PI: Cristina Ruiz Romero.

Members of team involved: Patricia Fernández, Carlos Fernández, Carmen Bejerano, Lucía Lourido, Flor Picchi.

Abstract: This project proposes to carry out a proteomic approach to identify and validate circulating biomarkers predictive of therapeutic response, which can be useful for the selection and optimization of biological therapies. These markers will be combined with other genetic and clinical data to obtain a predictive tool that can be used in clinical practice. The A Coruña Hospital cohort (PROCOAC) and preliminary data from GIR will be used for the identification of markers for therapy selection. Samples from the REMRABIT personalized medicine project will be employed for the identification of therapy optimization markers.

 

– Title: Identification and Validation of Therapeutic Targets in Diabetes-Associated OA: Role of Autophagy.

• Original Title: Identificación y validación de dianas terapéuticas en la artrosis asociada a diabetes: papel de la autofagia.

Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

Reference: PI17/02059 Dates: 01/01/2018- 31/12/2020 Budget: 111.320 €

PI: Beatriz Caramés Pérez.

Members of team involved: Jose Antonio Pinto Tasende, Uxía Nogueira Recalde, Noa Goyanes Rey, Elena Gismero Salmenor.

Abstract: In Aging and Osteoarthritis (OA), defects in cellular homeostasis, and in particular in autophagy, precede joint damage. OA is a complex and multifactorial disease, where systemic metabolic status plays a key role. In this sense, patients with Type 2 Diabetes (T2D) present more prevalent and severe OA, so it has been proposed as a new clinical phenotype. However, the mechanisms that define this effect are not fully understood. We have recently shown that there is a decrease in autophagy in chondrocytes and cartilage from patients with OA and T2D. These data suggest that the joint damage presented by patients with OA and T2D could be due to a failure of autophagy, provoking an accumulation of cellular products related to inflammatory and metabolic mediators. These observations represent a unique opportunity to identify and validate biomarkers associated with autophagy and could facilitate the development of therapeutic strategies to prevent joint damage associated with T2D.

 

– Title: Determination of predictive scores for the diagnosis and prognosis of knee osteoarthritis by the validation of protein biomarkers.

• Original Title: Determinación de índices predictivos de diagnóstico y pronóstico de artrosis de rodilla mediante la validación de biomarcadores protéicos.

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PI16/02124 Dates: 01/01/2017 – 31/12/2019 Budget: 224.152,50 €

• PI: Francisco Javier Blanco García.

• Members of team involved: Valentina Calamia, Natividad Oreiro, Patricia Fernández, Lucía Lourido.

• Abstract: This project aims to validate a panel of 20 proteins with potential biomarker utility for osteoarthritis in two independent cohorts: the American cohort (OAI) and the cohort from Hospital Universitario de A Coruña (PROCOAC). To perform this validation, two complementary targeted proteomics techniques will be used: mass spectrometry (MRM assays) and antibody microarrays. The use of these techniques on the incidence and progression subcohorts of OAI, and the subsequent external validation of the results in the PROCOAC cohort, would allow selecting the best biomarker candidates and obtaining predictive scores for diagnosis and prognosis of OA, with wide applicability in clinic.

 

– Title: Identification of Clinical Phenotypes on Osteoarthritis Disease through Big Data Approach.

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PIE16/00054 Dates: 01/01/2017 – 31/12/2019 Budget: 523.820,00 €

• PI: Francisco Javier Blanco García.

• Members of team involved: Ignacio Rego Pérez, Sara Relaño Fernández, Elena F Burguera.

• Abstract: OA causes significant comorbidity leading to the simultaneous manifestation of chronic, inflammatory and related diseases in the same patient. Here we aim to design a Biomedical Platform of Knowledge by means of Big Data analysis to integrate clinical and molecular information from well-characterized collections of samples from different cohorts (HIV, Rheumatic, Metabolic and Cardiovascular Disease). The designed platform will allow a comprehensive analysis of all available data to identify unknown OA clinical phenotypes, evaluate mtDNA haplogroups and mitochondrial dysfunction as potential biomarkers and to characterize OA phenotypes with an enhanced inflammatory scenario that takes place under concomitant psoriasis and/or HIV infection.

 

– Title: Clinical validation of genetic markers to predict persistent remission in rheumatoid arthritis patients treated with biological therapy (REMRABIT).

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PMP15/00032 Dates: 01/01/2016 – 31/12/2019 Budget: 980.305,70 €

• PI: Francisco Javier Blanco García.

• Members of team involved: Natividad Oreiro Villar; Jesús Carlos Fernández López; María Carmen Bejerano Herrería; Elena Gismero Salmador; Ignacio Rego Pérez; Elena F Burguera.

• Abstract: The goal of this project is to calculate the predictive value of 15 reported genetic polymorphisms (SNPs) associated with clinical remission in patients with Rheumatoid Arthritis (RA) treated with biological therapy. It is concurrently performed with a RCT conducted by the Rheumatology Service: “Evaluation of the clinical usefulness of standardized strategies for dose reduction protocol in patients with RA in clinical remission treated with biological therapies: Opened, randomized controlled and non-commercial study”. An associated multicenter sub-study was designed to include 400 patients. Analysis of the genetic background and other clinical variables of responders and non-responders will result in an algorithm to predict clinical remission.

– Title: “Identification of mitochondrial genetic markers of rapid progression of knee OA by next generation sequencing techniques”.

  • Members of team involved: Alejandro Durán Sotela

AUTONOMIC:

– Title: Peptide microarray for osteoarthritis diagnosis and monitoring.

Original Title: Microarray de Péptidos para el Diagnóstico y Monitorización de la Artrosis.

Funding Agency: Agencia Galega de Innovación, Xunta de Galicia.

Reference: IN855A 2016/35 Dates: 01/01/2018- 31/12/2019 Budget: 446.500€

PI: Francisco Javier Blanco García

Members of team involved: Cristina Ruiz Romero, Patricia Fernandez Puente, Valentina Calamia, Lucía Lourido Salas, Elena Fernández Burguera

Abstract: The objective of this project is to valorize a panel of 13 peptides (protein fractions), identified and academically validated, for the early diagnosis of osteoarthritis (OA) in human serum. The main output of the project is the licensing of the intellectual property of the panel to a consolidated company in the pharmaceutical sector.

 

– Title: Rheumatology Research Group (GIR). Group of Excellence.

Funding Agency: Xunta de Galicia. Consellería de Investigación, Desenvolvemento e Innovación.

Reference: IN607A2017/11 Dates: 01/01/2017 – 31/12/2020 Budget: €330.060

PI: Francisco J Blanco

Members of team involved: All Group.

 

– Title: Galician Network of Colorectal Cancer Research (REGICC).

Funding Agency: Xunta de Galicia. Consellería de Investigación, Desenvolvemento e Innovación

Reference: ED431D2017/23 Dates: 01/01/2017 – 31/12/2019 Budget: €120.000

Principal Investigator: Alejandro Pazos (University of A Coruña)

GIR Partner PI: Francisco J Blanco

Website: http://regicc.imedir.udc.es/es/sections/Default.aspx

Members of team involved: All Group.

 

– Title: Galician Network of Drugs Research and Development (REGID).

Funding Agency: Xunta de Galicia. Consellería de Investigación, Desenvolvemento e Innovación

Reference: ED431D 2017/16 Dates: 01/01/2017 – 31/12/2019 Budget: €120.000

Principal Investigator: María Isabel Loza García (Universidade de Santiago de Compostela)

GIR Partner PI: Francisco J Blanco

Website: http://regid.cesga.es/

Members of team involved: All Group.

 

PRIVATE FUNDING:

– Title: Targeting senescent cells in osteoarthritis: an innovative therapeutic approach (SEN-OA).

• Funding Agency: Foundation for Research in Rheumatology (Foreum).

• Reference: SEN-OA Dates: 01/01/2018 – 31/12/2021  Budget: 600.000€

• Principal Investigator: Noël D (Coordinator, Inserm UMR-1183, Montpellier)

• GIR Partner PI: Beatriz Caramés Pérez.

• Website:  http://www.foreum.org/sen_oa.cfm

Members of team involved: Uxía Nogueira Recalde, Irene Lorenzo Gómez.

• Abstract: The main risk factor for Osteoarthritis (OA) is ageing. An emerging concept for age-related diseases is that senescent cells accumulate with time and release SASP (senescence-associated secretory profile) products, which alter tissue functions. Accumulation of senescent cells during lifespan is believed to contribute to progressive tissue loss of functions. Specific elimination of these cells could prevent some age-associated diseases. Within the SEN-OA consortium, we propose a multifaceted approach combining innovative biomedical senescence models, ageing animal studies, human sample analyses and screening for senescence-targeting compounds for clinical application to (i) decipher the role of ageing-associated senescence mechanisms in the appearance of OA and (ii) develop innovative treatments for OA patients.

 

– Title: Chair in Tissue Engineering and Cell Therapy.

• Funding Body: BIOIBERICA S.A.

• Abstract: FJ Blanco holds the Chair in “Tissue Engineering and Cell Therapy” established in 2005, at the University of A Coruña, by BIOIBERICA S.A. The objectives of this Chair are: to analyze therapeutic value of chondroprotection in Osteoarthritis. Bioiberica is a biotechnology company specialized in the identification and extraction of biomolecules of high biological and therapeutic value from tissues of animal origin. Bioiberica is the leading Western producer of heparin and leader in Osteoarthritis and joint health for people and animals. This ongoing collaboration has resulted in a licensed product and more than 15 peer-reviewed scientific publications.

ISCIII NETWORKS

PROTEORED:

– Title: Platform of Proteomics, Genotyping and Cell Lines.

• Original Title: Plataforma de Proteómica, Genotipado y Líneas Celulares.

• Funding Agency: Instituto de Salud Carlos III.

• Reference: PT17/0019/0014 Dates: 01/01/2018 – 31/12/2020 Budget: 110.550€

• PI: Francisco Javier Blanco García.

• Members of team involved: Proteomics Unit GIR.

 

– Title: Plataforma de Recursos Biomoleculares y Bioinformáticos (PRB2).

• Funding Agency: ISCIII.

• Reference: P13/0001/0034 Dates: 01/01/2014- 31/12/2017 Budget: 239.250€

• PI: Francisco Javier Blanco Garcia.

• Website: http://www.proteored.org/

• Members of team involved: Cristina Ruiz-Romero, Patricia Fernández-Puente, Valentina Calamia, Lucía Lourido, Beatriz Rocha, María Camacho, Lucía González.

 

ProteoRed Multicentric Experiments:

– PME11.2 (2017)  – Phosphoproteomics (Part II).

– PME11 (2016)  Phosphoproteomics.

– PME10 (2015) – Relative Retention Times in Targeted Proteomics (R2T2).

– PME9 (2014) – Analysis of UPS2 Standard, Sigma Aldrich.

– PME8 (2013)  QTAPAS, Quantitative Targeted Analysis in Proteomics – An Assessment Study.

– PME7 (2012) – A Multi-Centric Study to Assess Reproducibility of Protein Quantification by SRM LC-MS Proteomic Analysis.

 

CIBER-BBN:

– Title: Centro de Investigación Biomédica en Red (CIBER-BBN).

• Funding Agency: ISCIII.

• Reference: CB06/01/0040 Dates: 01/01/2014 – 31/12/2018.

• PI: Cristina Ruiz Romero.

• Website: www.ciber-bbn.es

• Members of team involved: Joana Magalhaes, Elena F. Burguera, Mercedes Fernández Moreno, Natividad Oreiro, Tamara Hermida, Purificación Filgueira.

 

CIBER-BBN Intramural Projects:

– Title: Tailored Nanopatterning Scaffolds for Musculoskeletal Tissue Regeneration.

Principal Investigator: Josep Samitier.

GIR Partner PI: Cristina Ruiz Romero.

Dates: 01/01/2018 – N/D.

Partners: NANOMED-IBEC, Universidad Politécnica de Valencia (CBIT-UPV), NANOMEMB-UB, Bionand, Labret – Universidad de Málaga.

 

– Title: Development and validation of methods for the evaluation of osteoarthritis-related protein biomarkers useful for its diagnosis, monitoring and therapy 2. Acronym: OA-BIOMARK 2.

PI: Cristina Ruiz Romero.

Dates: 01/01/2018 – N/D.

Partners: Nanobiotechnology for Diagnostics (Nb4D), Nanoparticle and Peptide Chemical Group (NPCG), Biomaterials Centre, Universidad Politécnica de Valencia (CBIT-UPV)].

 

– Title: Osteoarticular Regeneration by Bioprinting.

PI: Luis M. Rodríguez Lorenzo.

GIR Partner PI: Joana Magalhaes.

Dates: 01/01/2018 – N/D.

Partners: GIR, INIBIC and GBP-CSIC.

 

– Title: Development and validation of methods for the evaluation of osteoarthritis-related protein biomarkers useful for its diagnosis, monitoring and therapy (OA-BIOMARK).

• PI: Cristina Ruiz Romero.

• Dates: 01/01/2016 – 31/12/2017.

• Partners: Nanobiotechnology for Diagnostics (Nb4D), Nanoparticle and Peptide Chemical Group (NPCG), Biomaterials Centre, Universidad Politécnica de Valencia (CBIT-UPV).

 

– Title: Nanopatterned Cell Carriers for Improved Architectural Communication Networks in Chondrogenesis towards Osteoarthritic Joint Repair (CHONDRONANONET-2).

• PI: Anna Lagunas (IBEC).

• GIR Partner PI: Cristina Ruiz Romero.

• Dates: 01/01/2016 – 31/12/2017.

• Partners: Universidad Politécnica de Valencia (CBIT-UPV), BIONAND, LABRET-UMA.

 

– Title: Multicomponent scaffolds for osteoarthritis treatment (MULTISCAFF).

• PI: Daniel Arcos Navarrete (UCM).

• GIR Partner PI: Elena F. Burguera.

• Dates: 01/01/2016 – 31/12/2017.

• Partners: Biomedical Engineering Institute, Instituto Tecnológico de Canarias.

 

– Title: Innovative biomedical tools for the early diagnosis and treatment of osteoporosis and osteoarthritis (OSTEOMIR).

• PI: María Rosa Aguilar de Armas (CSIC).

• GIR Partner PI: Joana Magalhaes.

• Dates: 01/01/2016 – 31/12/2017.

• Partners: Hospital Universitario Ramón y Cajal (HURC), Technische Universität München (TUM).

 

– Title: Nanopatterned Cell Carriers for Improved Architectural Communication Networks in Chondrogenesis towards Osteoarthritic Joint Repair (CHONDRONANONET).

• PI: Josep Samitier Martí (IBEC).

• GIR Partner PI: Cristina Ruiz Romero.

• Dates: 01/01/2014 – 31/12/2015.

• Partners: Universidad Politécnica de Valencia (CBIT-UPV), BIONAND, LABRET-UMA.

 

– Title: New Approaches for Cartilage Repair: biofunctionalized scaffolds and iPS (NACRE).

• PI: Cristina Ruiz Romero.

• Dates: 01/01/2012 – 31/12/2013.

• Partners: CBM-UPV, GABBRMAN-UVEG, GBBIT-IBEC, GBP-CSIC, GEMM-I3A, GTS-IBV, ITUS-INASMET, LABRET-UMA, TC-CIC, CSCP-IBEC.

 

– Title: New Approaches for Cartilage Repair (NACRE).

• PI: Francisco Javier Blanco García.

• Dates: 01/01/2010 – 31/12/2011.

• Partners: BITE-UAM, CBIT-UPV, CMRB-CI, GBBIT-IBEC, GBP-CSIC, GTS-IBV, ITUS-INASMET, LABRET-UMA, GEMM-I3A.

 

– Title: Development of New Concepts for Scaffolds and Cell Culture in Regenerative Medicine (BIO-SCAFF).

• PI: Josep Antón Planell Estany (IBEC).

• GIR Partner PI: Francisco J. Blanco.

• Dates: 01/01/2007 – 31/12/2009.

• Partners: GITBIT-UAH, IOBA-UVA, GEMM-I3A, GBBIT-IBEC, NANOMED-IBEC, GBP-CSIC, NANOMOL-CSIC, FIOBI-HULP, IBB-UAB, GTS-IBV, CBM-UPV, SLFPB-FHU, ITUS-INASMET, COFIBIC, BIOFORGE-UVA, BITE-UAM, NN-UMH, AM-UEX.

 

RIER:

– Title: Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER).

• Funding Agency: ISCIIII.

• Reference: RD16/0012/0002 Dates: 01/01/2017 – 31/12/2021 Budget: 168.624,50€

• PI: Francisco Javier Blanco García.

• Website: http://red-rier.org/

• Members of team involved: Carlos Fernández, JA Pinto, Ignacio Rego, Beatriz Caramés, Patricia Fernández, Valentina Calamia.

 

RIER Collaborative Projects:

– Title: Identification of circulating proteins associated with rheumatoid factor and anti-cyclic citrullinated protein antibodies.

• Partners: Antonio González (IDIS, CHUS).

 

– Title: Protein, lipid and metabolic profiling of synovial membranes from rheumatoid arthritis and psoriatic arthritis by mass spectrometry imaging.

• Partners: Juan D Cañete (IDIBAPS), Ron Heeren (Maastricht University).

 

– Title: Identification of an autoantibody profile for the prediction of response to anti-TNF therapies in rheumatoid arthritis.

• Partners: Antonio González (IDIS, CHUS), Peter Nilsson (SciLife Lab, Stockholm).

PREVIOUS PROJECTS

NATIONAL:

– Title: Design of a celular model usign transmitochondrial cybrids for the discovery of epigenetic biomarkers for the diagnosis of different OA phenotypes.

• Original Title: Diseño de un modelo celular de cíbridos transmitocondriales para la búsqueda de biomarcadores epigenéticos para el diagnóstico de distintos fenotipos de artrosis.

• Funding Agency: Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PI14/01254 Dates: 01/01/2015- 31/12/2017 Budget: 86.515 €

• PI: Ignacio Rego Pérez

• Members of team involved: Mercedes Fernández Moreno, Natividad Oreiro Villar, María Eugenia Vázquez Mosquera, Sara Relaño, Juan Fernández Tajes.

• Abstract: Methylation is a dynamic process prone to changes in the environment also involved in the phenotypic modulation that articular chondrocytes undergo during OA. In addition, nutrition and obesity are OA risk factors associated with alterations in DNA methylation. Mitochondria are involved in OA and modulate the DNA methylome, consequently the analysis of DNA methylome is a powerful tool to identify new OA biomarkers. The aim of this work is to create a chondrocyte-based cellular model of cytoplasmic cybrids to analyze the differential methylome, from exposure to oxidative stress, diet and inflammatory stimuli on different mitochondrial backgrounds to design a classifier that allow the identification of different OA phenotypes.

 

– Title: Validation of osteoarthritis protein biomarkers using targeted proteomics for the development of an in vitro diagnostic test.

• Original Title: Validación de biomarcadores proteicos de artrosis mediante proteómica dirigida para el desarrollo de un método de diagnóstico in vitro.

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PI14/01707 Dates: 01/01/2015- 31/12/2017 Budget: 134.915€

• PI: Cristina Ruiz Romero

• Members of team involved: Patricia Fernández, Natividad Oreiro, Valentina Calamia, María Camacho, Lucía González, Flor Picchi

• Abstract: The objective of this project is to develop three complementary targeted proteomic techniques in order to validate a panel of 200 protein biomarkers of Osteoarthritis. We will employ the following technologies: 1) targeted mass spectrometry (MRM assays); 2) analytical protein microarrays and 3) hybrid methodologies, involving immunoaffinity enrichment and subsequently mass spectrometry. The use of these techniques on serum and synovial fluid samples will allow validating the best candidates and developing a method for the molecular in vitro diagnosis of osteoarthritis that could be easily translated to the clinical routine and is potentially patentable.

 

– Title: Targeting Cartilage Aging to Identify Osteoarthritis Therapeutics.

• Original Title: Identificación de moléculas reguladoras del envejecimiento articular para el tratamiento de la artrosis.

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PI14/01324 Dates: 01/01/2015- 31/12/2018 Budget: 78.226,50€

• PI: Beatriz Caramés Pérez

• Members of team involved: Madalena Ribeiro, María José Sanchez Dopico, Luis Antonio García Rodriguez

• Abstract: Effective treatments for osteoarthritis (OA) are not available. Advances in mechanisms in aging-related diseases, including OA, have led to the concept that the failure of cellular homeostasis mechanisms, such as, autophagy can cause extracellular matrix destruction and cell death. In this sense, pharmacological stimulation of autophagy has anti-aging effects and may promote longevity. Chondrocytes are required for maintenance of cartilage integrity. With aging, chondrocytes function is limited, contributing to an imbalance in anabolic and catabolic activity and induce cellular senescence. These observations provide a unique opportunity to study cartilage aging with the objective to explore the therapeutic potential of pharmacological prevention of chondrocyte senescence and autophagy.

 

– Title: CICA-INIBIC Consortium.

• Funding Agency: Xunta de Galicia.

• Reference: AGRUP2015/05 Dates: 01/01/2015 – 31/12/2017 Budget: €500.000

• PI: Jaime Rodríguez González (UDC)

• GIR Partner PI: Francisco Javier Blanco García

• Members of team involved: Joana Magalhaes, Elena F. Burguera, Tamara Hermida, Cristina Ruiz Romero, Mercedes Fernández Moreno.

• Abstract: GIR is a founding member of the Strategic Consortium CICA-INIBIC that integrates 23 research groups from both the Advanced Scientific Research Center (CICA) and INIBIC, combining research in areas such as chemistry, biology and basic and clinical biomedical research in which the groups are international referents. Strategic Consortium CICA-INIBIC is defined as a multidisciplinary and synergic environment focused on efficiently address current biomedical, technological and environmental challenges through research, training and comprehensive solutions to generate scientific and economic value, and social progress.

 

– Title: Design of a celular model usign transmitochondrial cybrids for the discovery of epigenetic biomarkers for the diagnosis of different OA phenotypes.

• Original Title: Diseño de un modelo celular de cíbridos transmitocondriales para la búsqueda de biomarcadores epigenéticos para el diagnóstico de distintos fenotipos de artrosis.

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PI14/01254 Dates: 01/01/2015 – 31/12/2017  Budget: 86.515 €

• PI: Ignacio Rego Pérez.

• Members of team involved: Mercedes Fernández Moreno, Natividad Oreiro Villar, María Eugenia Vázquez Mosquera, Sara Relaño, Juan Fernández Tajes.

• Abstract: Methylation is a dynamic process prone to changes in the environment also involved in the phenotypic modulation that articular chondrocytes undergo during OA. In addition, nutrition and obesity are OA risk factors associated with alterations in DNA methylation. Mitochondria are involved in OA and modulate the DNA methylome, consequently the analysis of DNA methylome is a powerful tool to identify new OA biomarkers. The aim of this work is to create a chondrocyte-based cellular model of cytoplasmic cybrids to analyze the differential methylome, from exposure to oxidative stress, diet and inflammatory stimuli on different mitochondrial backgrounds to design a classifier that allow the identification of different OA phenotypes.

 

– Title: Validation of osteoarthritis protein biomarkers using targeted proteomics for the development of an in vitro diagnostic test.

• Original title: Validación de biomarcadores proteicos de artrosis mediante proteómica dirigida para el desarrollo de un método de diagnóstico in vitro.

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PI14/01707 Dates: 01/01/2015 – 31/12/2017  Budget: 134.915€

• PI: Cristina Ruiz Romero.

• Members of team involved: Patricia Fernández, Natividad Oreiro, Valentina Calamia, María Camacho, Lucía González, Flor Picchi.

• Abstract: The objective of this project is to develop three complementary targeted proteomic techniques in order to validate a panel of 200 protein biomarkers of Osteoarthritis. We will employ the following technologies: 1) targeted mass spectrometry (MRM assays); 2) analytical protein microarrays and 3) hybrid methodologies, involving immunoaffinity enrichment and subsequently mass spectrometry. The use of these techniques on serum and synovial fluid samples will allow validating the best candidates and developing a method for the molecular in vitro diagnosis of osteoarthritis that could be easily translated to the clinical routine and is potentially patentable.

 

– Title: Identification of Novel Molecules Targeting Cartilage Aging as Osteoarthritis Therapeutics.

• Original Title: Identificación de moléculas reguladoras del envejecimiento articular para el tratamiento de la artrosis.

• Funding Agency: Fondo de Investigación Sanitaria. ISCIII.

• Reference: PI14/01324 Dates: 01/01/2015 – 31/12/2017  Budget: 78.226,50€

• PI: Beatriz Caramés Pérez.

• Members of team involved: 4.

• Abstract: Effective treatments for osteoarthritis (OA) are not available. Advances in mechanisms in aging-related diseases, including OA, have led to the concept that the failure of cellular homeostasis mechanisms, such as, autophagy can cause extracellular matrix destruction and cell death. In this sense, pharmacological stimulation of autophagy has anti-aging effects and may promote longevity. Chondrocytes are required for maintenance of cartilage integrity. With aging, chondrocytes function is limited, contributing to an imbalance in anabolic and catabolic activity and induce cellular senescence. These observations provide a unique opportunity to study cartilage aging with the objective to explore the therapeutic potential of pharmacological prevention of chondrocyte senescence and autophagy.

 

– Title: CICA-INIBIC Consortium.

• Funding Agency: Xunta de Galicia.

• Reference: AGRUP2015/05 Dates: 2015 – 2017 Budget: €500.000

• PI: Jaime Rodríguez González (UDC).

• GIR Partner PI: Francisco Javier Blanco García.

• Members of team involved: Joana Magalhaes, Elena F. Burguera, Tamara Hermida, Cristina Ruiz Romero, Mercedes Fernández Moreno.

• Abstract: GIR is a founding member of the Strategic Consortium CICA-INIBIC that integrates 23 research groups from both the Advanced Scientific Research Center (CICA) and INIBIC, combining research in areas such as chemistry, biology and basic and clinical biomedical research in which the groups are international referents. Strategic Consortium CICA-INIBIC is defined as a multidisciplinary and synergic environment focused on efficiently address current biomedical, technological and environmental challenges through research, training and comprehensive solutions to generate scientific and economic value, and social progress.

 

AUTONOMIC:

– Title: CICA-INIBIC Consortium.

Funding Agency: Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria

Reference: AGRUP2015/05 Dates: 01/01/2015 – 30/11/2017 Budget: €500.000

Principal Investigator: Jaime Rodríguez González (Universidade da Coruña)

GIR Partner PI: Francisco J Blanco

Members of team involved: Cristina Ruiz Romero, Joana Magalhães, Elena F. Burguera, Tamara Hermida, Natividad Oreiro, Purificación Filgueira, Cristina Rodríguez Pereira, Lucía Gato.